SK288038B6 - Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection - Google Patents

Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection Download PDF

Info

Publication number: SK288038B6
Authority: SK; Slovakia
Prior art keywords: weeks; patients; interferon alpha; hcv; treatment
Prior art date: 1998-05-15

Application number

SK1710-2000A

Other languages

English (en)

Slovak (sk)

Other versions

SK17102000A3 (sk

Inventor

Janice K Albrecht

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-15

Filing date

1999-05-13

Publication date

2013-01-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22151354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK288038(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-05-13 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2001-05-10 Publication of SK17102000A3 publication Critical patent/SK17102000A3/sk

2013-01-02 Publication of SK288038B6 publication Critical patent/SK288038B6/sk

Links

IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract description 96
229960000329 ribavirin Drugs 0.000 title claims abstract description 96
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 96
108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 85
102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 85
208000020403 chronic hepatitis C virus infection Diseases 0.000 title claims abstract description 20
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
238000004519 manufacturing process Methods 0.000 title abstract description 3
238000011282 treatment Methods 0.000 claims abstract description 130
230000000840 anti-viral effect Effects 0.000 claims abstract description 30
230000003612 virological effect Effects 0.000 claims description 77
102000014150 Interferons Human genes 0.000 claims description 44
108010050904 Interferons Proteins 0.000 claims description 44
229940079322 interferon Drugs 0.000 claims description 42
210000002966 serum Anatomy 0.000 claims description 35
102100040018 Interferon alpha-2 Human genes 0.000 claims description 19
108010079944 Interferon-alpha2b Proteins 0.000 claims description 19
208000015181 infectious disease Diseases 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 15
230000006378 damage Effects 0.000 claims description 6
238000003753 real-time PCR Methods 0.000 claims description 4
238000002648 combination therapy Methods 0.000 abstract description 111
230000004044 response Effects 0.000 description 143
230000002459 sustained effect Effects 0.000 description 96
239000000902 placebo Substances 0.000 description 41
229940068196 placebo Drugs 0.000 description 41
238000009097 single-agent therapy Methods 0.000 description 36
238000001574 biopsy Methods 0.000 description 26
230000006872 improvement Effects 0.000 description 22
238000011529 RT qPCR Methods 0.000 description 20
238000000034 method Methods 0.000 description 20
206010061218 Inflammation Diseases 0.000 description 18
230000004054 inflammatory process Effects 0.000 description 18
208000005176 Hepatitis C Diseases 0.000 description 16
201000010099 disease Diseases 0.000 description 16
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 16
210000004185 liver Anatomy 0.000 description 14
230000002440 hepatic effect Effects 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
230000009265 virologic response Effects 0.000 description 13
208000006154 Chronic hepatitis C Diseases 0.000 description 12
208000010710 hepatitis C virus infection Diseases 0.000 description 12
229940065638 intron a Drugs 0.000 description 11
241000700605 Viruses Species 0.000 description 10
238000012317 liver biopsy Methods 0.000 description 10
238000002203 pretreatment Methods 0.000 description 10
108010078049 Interferon alpha-2 Proteins 0.000 description 9
239000000203 mixture Substances 0.000 description 8
238000010606 normalization Methods 0.000 description 8
230000037396 body weight Effects 0.000 description 7
229920001223 polyethylene glycol Polymers 0.000 description 7
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 7
238000012360 testing method Methods 0.000 description 7
238000000729 Fisher's exact test Methods 0.000 description 6
230000008859 change Effects 0.000 description 6
208000019425 cirrhosis of liver Diseases 0.000 description 6
230000008034 disappearance Effects 0.000 description 6
229960003507 interferon alfa-2b Drugs 0.000 description 6
238000000611 regression analysis Methods 0.000 description 6
238000010839 reverse transcription Methods 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
206010016654 Fibrosis Diseases 0.000 description 5
230000007882 cirrhosis Effects 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
230000002035 prolonged effect Effects 0.000 description 5
239000000523 sample Substances 0.000 description 5
238000002105 Southern blotting Methods 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000005259 measurement Methods 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000000875 corresponding effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000008176 lyophilized powder Substances 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
238000011269 treatment regimen Methods 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
102100023915 Insulin Human genes 0.000 description 2
102100034343 Integrase Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
208000006454 hepatitis Diseases 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
229920000233 poly(alkylene oxides) Polymers 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
238000011268 retreatment Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
239000005695 Ammonium acetate Substances 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241001227713 Chiron Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
206010019837 Hepatocellular injury Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007397 Species specific proteins Human genes 0.000 description 1
108020005719 Species specific proteins Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
229940043376 ammonium acetate Drugs 0.000 description 1
235000019257 ammonium acetate Nutrition 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229930003836 cresol Natural products 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000008935 histological improvement Effects 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000028993 immune response Effects 0.000 description 1
229940124622 immune-modulator drug Drugs 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
229960003521 interferon alfa-2a Drugs 0.000 description 1
108010055511 interferon alfa-2c Proteins 0.000 description 1
108010006088 interferon alfa-n1 Proteins 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000009533 lab test Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000018191 liver inflammation Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
108010092851 peginterferon alfa-2b Proteins 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000008593 response to virus Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

SK1710-2000A 1998-05-15 1999-05-13 Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection SK288038B6 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7956698A	1998-05-15	1998-05-15
PCT/US1999/007037 WO1999059621A1 (en)	1998-05-15	1999-05-13	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection

Publications (2)

Publication Number	Publication Date
SK17102000A3 SK17102000A3 (sk)	2001-05-10
SK288038B6 true SK288038B6 (en)	2013-01-02

Family

ID=22151354

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1710-2000A SK288038B6 (en)	1998-05-15	1999-05-13	Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection

Country Status (22)

Country	Link
EP (3)	EP0956861B1 (da)
JP (2)	JP5281726B2 (da)
KR (1)	KR100694345B1 (da)
CN (1)	CN1230198C (da)
AR (1)	AR019551A1 (da)
AT (1)	ATE216591T1 (da)
AU (2)	AU766597B2 (da)
BR (1)	BR9910505A (da)
CA (1)	CA2331823A1 (da)
CZ (1)	CZ300540B6 (da)
DE (1)	DE69901321T2 (da)
DK (1)	DK0956861T3 (da)
ES (1)	ES2172288T3 (da)
HU (1)	HU230432B1 (da)
IL (3)	IL139220A0 (da)
MY (1)	MY129244A (da)
NO (1)	NO330715B1 (da)
NZ (1)	NZ507621A (da)
PT (1)	PT956861E (da)
SK (1)	SK288038B6 (da)
TW (1)	TWI277424B (da)
WO (1)	WO1999059621A1 (da)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
WO2000037110A2 (en) *	1998-12-18	2000-06-29	Schering Corporation	Ribavirin-pegylated interferon alfa induction hcv combination therapy
CA2384326A1 (en) *	1999-12-23	2001-06-28	Johnson Lau	Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
JP4536194B2 (ja) *	2000-02-17	2010-09-01	大日本住友製薬株式会社	安定な注射用製剤
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
EP1736478B1 (en)	2000-05-26	2015-07-22	IDENIX Pharmaceuticals, Inc.	Methods and compositions for treating flaviviruses and pestiviruses
AU2002213343A1 (en) *	2000-10-18	2002-04-29	Schering Corporation	Ribavirin-pegylated interferon alfa HCV combination therapy
EP1435974A4 (en)	2001-09-28	2006-09-06	Idenix Cayman Ltd	METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
CA2466228A1 (en) *	2001-11-09	2003-08-07	Biomedicines, Inc.	Method for treating diseases with omega interferon
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
TW200500375A (en)	2002-06-28	2005-01-01	Idenix Cayman Ltd	Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CN1678326A (zh)	2002-06-28	2005-10-05	埃迪尼克斯(开曼)有限公司	用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
NZ537662A (en)	2002-06-28	2007-10-26	Idenix Cayman Ltd	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en)	2002-06-28	2009-10-27	Idenix Pharmaceuticals, Inc.	Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
LT1576138T (lt)	2002-11-15	2017-06-26	Idenix Pharmaceuticals Llc	2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en)	2002-12-12	2004-06-30	Idenix (Cayman) Limited	Process for the production of 2'-branched nucleosides
WO2004084796A2 (en) *	2003-03-28	2004-10-07	Pharmasset Ltd.	Compounds for the treatment of flaviviridae infections
CA2520148A1 (en) *	2003-04-01	2004-12-23	Intermune, Inc.	Compositions and methods for treating coronavirus infection and sars
EP1613342A1 (en) *	2003-04-17	2006-01-11	Ares Trading S.A.	Interferon beta in severe acute respiratory syndrome (sars)
HUE029877T2 (en)	2003-05-30	2017-04-28	Gilead Pharmasset Llc	Modified fluorinated nucleoside analogues
US7482149B2 (en) *	2003-06-09	2009-01-27	Genome Institute Of Singapore	Inhibition of SARS coronavirus infection with clinically approved antiviral drugs
JP2007501806A (ja) *	2003-08-13	2007-02-01	ハワードジェイ．スミスアンドアソシエイツピーティーワイエルティーディー	ウィルス感染を治療する方法
AR045870A1 (es) *	2003-10-11	2005-11-16	Vertex Pharma	Terapia de combinacion para la infeccion de virus de hepatitis c
CN101023094B (zh)	2004-07-21	2011-05-18	法莫赛特股份有限公司	烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en)	2004-09-14	2013-07-23	Gilead Pharmasset Llc	Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
TW201424733A (zh) *	2004-10-29	2014-07-01	Vertex Pharma	劑量型式
CA2636527C (en) *	2006-01-09	2016-05-17	Romark Laboratories, L.C.	Viral hepatitis treatment
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
WO2009015336A2 (en)	2007-07-25	2009-01-29	Biolex Therapeutics, Inc.	Controlled release interferon drug products and treatment of hcv infection using same
TW200946541A (en)	2008-03-27	2009-11-16	Idenix Pharmaceuticals Inc	Solid forms of an anti-HIV phosphoindole compound
RU2369403C1 (ru) *	2008-05-22	2009-10-10	Сергей Юрьевич Родионов	Способ лечения хронических вирусных гепатитов
PA8855601A1 (es)	2008-12-23	2010-07-27		Forformidatos de nucleósidos
AU2009329872B2 (en)	2008-12-23	2016-07-07	Gilead Pharmasset Llc	Synthesis of purine nucleosides
NZ593649A (en)	2008-12-23	2013-11-29	Gilead Pharmasset Llc	Nucleoside analogs
WO2010129947A2 (en)	2009-05-08	2010-11-11	Sciclone Pharmaceuticals, Inc.	Alpha thymosin peptides as vaccine enhancers
US8618076B2 (en)	2009-05-20	2013-12-31	Gilead Pharmasset Llc	Nucleoside phosphoramidates
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
SG184324A1 (en)	2010-03-31	2012-11-29	Gilead Pharmasset Llc	Nucleoside phosphoramidates
CN103179974A (zh) *	2010-10-05	2013-06-26	诺华有限公司	丙型肝炎病毒感染的新疗法
CA2818853A1 (en)	2010-11-30	2012-06-07	Gilead Pharmasset Llc	2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2680859B1 (en) *	2011-03-02	2022-04-27	Jerome Schentag	Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination with a hepatitis c virus infection
EP2709613B2 (en)	2011-09-16	2020-08-12	Gilead Pharmasset LLC	Methods for treating hcv
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
EP2950786B1 (en)	2013-01-31	2019-11-27	Gilead Pharmasset LLC	Combination formulation of two antiviral compounds
PT3038601T (pt)	2013-08-27	2020-06-30	Gilead Pharmasset Llc	Formulação combinada de dois compostos antivirais

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211771A (en)	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
US4492537A (en)	1982-12-10	1985-01-08	Awerkamp John B	Fluid-operated oil or water well pump
US4766106A (en)	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja)	1986-03-10	1996-07-10	エフ・ホフマン―ラロシユアーゲー	化学修飾蛋白質，その製造法および中間体
US5595732A (en)	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5382657A (en)	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
ATE214940T1 (de)	1993-11-10	2002-04-15	Enzon Inc	Verbesserte interferon-polymerkonjugate
US5766582A (en)	1994-10-11	1998-06-16	Schering Corporation	Stable, aqueous alfa interferon solution formulations
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	インターフェロンを含む液体製剤
US6387365B1 (en) *	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
DE69632062T2 (de) *	1995-11-02	2004-11-18	Schering Corp.	Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
TW517067B (en)	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
WO1999008729A1 (en)	1997-08-13	1999-02-25	Boston Scientific Limited	Loading and release of water-insoluble drugs
ES2186660T3 (es) *	1997-09-21	2003-05-16	Schering Corp	Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.

1999
- 1999-05-13 AU AU38600/99A patent/AU766597B2/en not_active Withdrawn - After Issue
- 1999-05-13 IL IL13922099A patent/IL139220A0/xx unknown
- 1999-05-13 EP EP99303729A patent/EP0956861B1/en not_active Expired - Lifetime
- 1999-05-13 CA CA002331823A patent/CA2331823A1/en not_active Abandoned
- 1999-05-13 MY MYPI99001891A patent/MY129244A/en unknown
- 1999-05-13 JP JP2000549285A patent/JP5281726B2/ja not_active Expired - Lifetime
- 1999-05-13 AT AT99303729T patent/ATE216591T1/de active
- 1999-05-13 WO PCT/US1999/007037 patent/WO1999059621A1/en not_active Ceased
- 1999-05-13 EP EP01130613A patent/EP1213029A1/en not_active Withdrawn
- 1999-05-13 CN CNB998085960A patent/CN1230198C/zh not_active Expired - Lifetime
- 1999-05-13 ES ES99303729T patent/ES2172288T3/es not_active Expired - Lifetime
- 1999-05-13 SK SK1710-2000A patent/SK288038B6/sk not_active IP Right Cessation
- 1999-05-13 TW TW088107774A patent/TWI277424B/zh not_active IP Right Cessation
- 1999-05-13 CZ CZ20004177A patent/CZ300540B6/cs not_active IP Right Cessation
- 1999-05-13 KR KR1020007012784A patent/KR100694345B1/ko not_active Expired - Lifetime
- 1999-05-13 PT PT99303729T patent/PT956861E/pt unknown
- 1999-05-13 HU HU0103423A patent/HU230432B1/hu unknown
- 1999-05-13 DE DE69901321T patent/DE69901321T2/de not_active Expired - Lifetime
- 1999-05-13 EP EP10181927A patent/EP2305287A1/en not_active Withdrawn
- 1999-05-13 BR BR9910505-5A patent/BR9910505A/pt not_active Application Discontinuation
- 1999-05-13 DK DK99303729T patent/DK0956861T3/da active
- 1999-05-14 AR ARP990102303A patent/AR019551A1/es unknown
2000
- 2000-10-18 NZ NZ507621A patent/NZ507621A/xx not_active IP Right Cessation
- 2000-10-23 IL IL139220A patent/IL139220A/en not_active IP Right Cessation
- 2000-11-14 NO NO20005755A patent/NO330715B1/no not_active IP Right Cessation
2005
- 2005-10-10 AU AU2005220271A patent/AU2005220271B9/en not_active Expired
2010
- 2010-07-27 IL IL207259A patent/IL207259A/en not_active IP Right Cessation
2011
- 2011-04-07 JP JP2011085606A patent/JP2011173898A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR100694345B1 (ko)	2007-03-12
NO20005755D0 (no)	2000-11-14
CN1230198C (zh)	2005-12-07
EP1213029A1 (en)	2002-06-12
AU2005220271B9 (en)	2010-12-09
CN1309568A (zh)	2001-08-22
HUP0103423A3 (en)	2003-11-28
AU2005220271A1 (en)	2005-11-03
PT956861E (pt)	2002-08-30
NO20005755L (no)	2001-01-12
CZ20004177A3 (cs)	2001-04-11
DE69901321T2 (de)	2002-12-12
JP2011173898A (ja)	2011-09-08
HU230432B1 (hu)	2016-06-28
EP2305287A1 (en)	2011-04-06
AU3860099A (en)	1999-12-06
NO330715B1 (no)	2011-06-20
AR019551A1 (es)	2002-02-27
IL207259A (en)	2016-08-31
AU2005220271B8 (en)	2010-11-18
BR9910505A (pt)	2001-01-02
HUP0103423A2 (hu)	2002-01-28
ES2172288T3 (es)	2002-09-16
JP2002515453A (ja)	2002-05-28
IL207259A0 (en)	2010-12-30
CZ300540B6 (cs)	2009-06-10
CA2331823A1 (en)	1999-11-25
NZ507621A (en)	2002-11-26
AU766597B2 (en)	2003-10-16
AU2005220271B2 (en)	2005-11-03
EP0956861A1 (en)	1999-11-17
WO1999059621A1 (en)	1999-11-25
JP5281726B2 (ja)	2013-09-04
MY129244A (en)	2007-03-30
HK1021131A1 (en)	2000-06-02
KR20010043624A (ko)	2001-05-25
IL139220A0 (en)	2001-11-25
IL139220A (en)	2013-02-28
DK0956861T3 (da)	2002-07-01
DE69901321D1 (de)	2002-05-29
ATE216591T1 (de)	2002-05-15
TWI277424B (en)	2007-04-01
EP0956861B1 (en)	2002-04-24
SK17102000A3 (sk)	2001-05-10

Legal Events

Date

Code

Title

Description

2013-01-02

TC4A

Change of owner's name

Owner name: MERCK SHARP & DOHME CORP., RAHWAY, NJ, US

Effective date: 20121108

2019-07-02

MK4A

Patent expired

Expiry date: 20190513

Publication	Publication Date	Title
SK288038B6 (en)	2013-01-02	Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
US6472373B1 (en)	2002-10-29	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en)	2001-01-09	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
TW568787B (en)	2004-01-01	Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US20020127203A1 (en)	2002-09-12	Ribavirin-pegylated interferon alfa HCV combination therapy
WO2000037110A2 (en)	2000-06-29	Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en)	2004-11-30	Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037097A1 (en)	2000-06-29	Ribavirin-interferon alfa induction hcv combination therapy
MXPA00011198A (en)	2001-07-31	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
HK1154495A (en)	2012-04-27	Combination therapy for eradicating detectable hcv-rna in antiviral treatment naive patients having chronic hepatitis c infection
HK1044464A (en)	2002-10-25	Combination therapy for eradicating detectable hcv-rna in antiviral treatment naive patients having chronic hepatitis c infection
HK1021131B (en)	2002-08-16	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis c infection
MXPA01006161A (en)	2001-12-13	Ribavirin-pegylated interferon alfa induction hcv combination therapy
CZ2000788A3 (cs)	2000-06-14	Použití ribavirinu pro výrobu farmaceutických prostředků, použití interferonů alfa pro výrobu farmaceutických prostředků a farmaceutické výrobky
MXPA98007284A (en)	1999-09-20	Combination therapy to eradicate vhc-rna detectable in patients who have infection of hepatitis c cron